celgene corporation pharmaceutical company makes cancer immunology drugs major product revlimid lenalidomide used treatment multiple myeloma also certain anemias company incorporated delaware headquartered summit new jersey subsidiary bristol myers squibb celgene originally unit celanese celanese completed corporate spinoff celgene following merger celanese american august celgene acquired signal pharmaceuticals inc privately held company developed pharmaceuticals regulate diseaserelated signal pharmaceuticals rebranded celgene research san december celgene acquired anthrogenesis privately held new jerseybased biotherapeutics company cord blood banking business developing technology recovery stem cells placental tissues following completion fullterm successful pregnancies anthrogenesis rebranded celgene cellular celgene certified mckesson specialty specialty pharmacy one group pharmacies contracted launch lenalidomide revlimid specialty drug lenalidomide available distribution network consisting specialty pharmacies contracted march celgene acquired pharmion corporation january celgene acquired gloucester june celgene agreed acquire abraxis purchased biotechnology company billion expansion drugs attack solid abraxis produced abraxane cancerfighting drug given high november celgene relocated united kingdom headquarters windsor berkshire stockley park near heathrow airport also home glaxosmithklines uk january celgene agreed acquire avila therapeutics inc privately held biotechnology company million million citing market capitalization billion stock appreciation celgene forbes magazines number ranked drug company celgene oncomed pharmaceuticals joined cancer stem cell therapeutic development agreement demcizumab five biologics oncomeds year sutro biopharma entered agreement celgene corporation discover develop multispecific antibodies antibody drug conjugates followed december collaboration two companies focused field april celgene announced collaboration astrazeneca worth million study phase iii immunooncology drug candidate month celgene announced would acquire quanticel million order enhance cancer drug celgene invested quanticel april june celgene announced licensed lyceras rorgamma agonist portfolio million develop phase lead compound treatment inflammatory bowel disease licensing opportunity gave celgene option acquire july company announced would acquire receptos billion move strengthen companys inflammation immunology may company announced would launch partnership agios pharmaceuticals developing metabolic immunooncology october company acquired engmab ag january company announced would acquire delinia million increasing companys autoimmune disease therapy january celgene announced would acquire impact biomedicines billion adding fedratinib kinase inhibitor potential treat also january company announced would acquire juno therapeutics companys summit headquarters located along main line abandoned rahway valley railroad advocated railbeds conversion pedestrian cyclist linear park rail january company announced would acquired bristolmyers squibb billion billion including deal would become largest pharmaceutical company acquisition celgene shareholders would receive one bmy share well cash celgene share held valuing celgene share representing premium previous days closing activist investor starboard value lp opposed deal nominating five alternative potential directors bristolmyers deal approved shareholders april august amgen announced would acquire otezla drug programme celgene billion part celgene bristolmyers squibbs merger deal bristolmyers acquisition closed november november bristolmyers squibb bms announced completed acquisition celgene following receipt regulatory approval government authorities required merger agreement announced april approval bristolmyers squibb celgene following illustration companys major mergers acquisitions historical predecessors comprehensive list march bob hugin companys long serving ceo retired position took role executive bob hugin succeeded ceo role mark time jacqualyn fouse named companys president coo fouse joined company effective june dr fouse purportedly step succeeded scott smith president companys global inflammation immunology franchise joined company dr fouse voted board directors april fiscal year celgene reported earnings billion annual revenue billion increase previous fiscal cycle celgenes shares traded per share market capitalization valued billion november celgene focused oncology cancer drugs include revlimid lenalidomide pomalyst pomalidomide immunology drug otezla apremilast accounted around companys total revenue july celgene received approval fda market thalomid acute treatment cutaneous manifestations moderate severe april celgene reached agreement novartis pharma ag license dmph celgenes chirally pure version ritalin fda subsequently granted approval market dmph focalin november december celgene received approval fda market revlimid treatment patients transfusiondependent anemia due low mds associated deletion cytogenetic abnormality without additional cytogenetic abnormalities focalin xr later launched celgene novartis may celgene received approval thalomid combination dexamethasone treatment patients newly diagnosed multiple myeloma june celgene received full marketing authorization revlimid combination dexamethasone treatment patients multiple myeloma received least one prior therapy european commission dr reddys laboratories requested celgene refused provide samples celgenes anticancer drug thalomid thalidomide dr reddys laboratories sought material bioequivalency studies required bring generic version thalidomide market response refusal dr reddys laboratories filed citizens petition fda asking agency adopt procedures would ensure generic applicants right buy sufficient samples perform bioequivalence testing drugs subject rems distribution restrictions celgene denied behaved anticompetitively arguing legislative history strongly suggested congress considered rejected proposed guaranteed access procedure like one proposed dr reddys celgene argued requiring innovator companies sell products potential generic competitors would violate intellectual property rights subject liability risks event patients harmed dr reddys studies celgene top list companies fda identified refusing release samples competitors create generic manufacturer lannett company initiated antitrust litigation accused celgene using rems thalomid thalidomide violate antimonopolization provisions sherman act early district court denied celgenes motion dismiss case set trial beginning february parties settled trial began thereby postponing judicial review antitrust claims premised alleged abuse rems distribution july celgene agreed pay million government agencies settle allegations caused submission false claims fraudulent claims nonreimbursable uses drugs revlimid thalomid medicare state medicaid july celgene disclosed resolved matter full million including fees case brought false claims act beverly brown former celgene sales httpsenwikipediaorgwikicelgene